Latest News

Track & Trace Hospital Assets

OLVG implemented Performance Flow to track&trace their mobile medical assets (like infusion pumps) within the hospital. This time and cost saving application is very well received and now more hospitals are moving to implement the solution.

Within OLVG all mobile medical devices are uniquely tagged and receivers are placed throughout the entire hospital. All devices can be exactly located, which is a major timesaver for medical staff since they don't have to search for assets. Saved time that can be spent on delivering more personal care to patients. Hospital management can monitor the performance of each individual asset and finetune the need for more or less assets. Maintenance can be streamlined so down time of valuable assets can be kept to a minimum. Currently the application is being expanded to not only track&trace mobile assets, but also patients. This can for instance streamline the patient flow in the emergency departments to increase healthcare or keep track of patients with Alzheimer's disease.

RADventure and Philips joined forces to create this state of art solution for hospitals.

More information:



Unified Screening Platform (USP) for Screening COVID-19

The world is experiencing a heavy burden with the coronavirus disease pandemic (also called COVID-19 or SARS-CoV-2). Almost all countries are preventing contamination and treating patients the best they can. Currently, the main focus is on treatment, but as the pandemic develops, the need for a structured COVID-screening program is growing massively. This is because quarantining the entire population for several months or perhaps several years is not feasible: there needs to be a structured approach for un-quarantining (parts of) the population. We foresee that large population screening programs will be a piece of this complex strategic puzzle.

At this moment we are noticing an upcoming demand for national data management systems to support these large population based screening programs. Both the screening to determine whether a person is infected (for example performing a blood test, oral swab test or a CT-scan) and the screening wether a person already had the disease (using antibody tests) will be needed. With more than 25 years of experience in large scale screening programs in countries all over the world, RADventure supports you to conduct these kind of programs with our Unified Screening Platform (USP).

USP is a flexible data management software environment that provides what is needed to implement large scale screening programs. With USP, the population can be organized in target groups based on different parameters (such as the person's age, gender, living area, previous studies results, etc). Based on these parameters each individual client is invited for a specific workflow and tracked from the first contact until the end of the defined screening workflow. The planning for the screening program can be set for the whole population or incrementally, prioritizing invitations based on specific criteria. Doing so it is possible to invite clients for a specific workflow, and/or area, or invite a selected group to a specific Screening Unit or specific workflow. Regarding planning and monitoring, USP has a Central Unit that can configure, plan and monitor different Screening Units (fixed and/or mobile). Due to the modular architecture, USP is flexible and ready to be integrated in other health care environments (like Hospital Information Systems and Laboratory Information Systems).

We are happy to advise and support you on the (data) management part of COVID-19 screening programs.

Cervical Cancer Screening program started on Curaçao

in September 2019, after several months of development, preparation and testing, the Cervical Cancer Screening program (CIS-FP) went live Curaçao  This Screening program is executed bij Fundashon Prevenshon. The workflow is based on cytology and/or HPV, depending on age. The system is designed with a planning module to create invitations with or without an appointment. Clients are invited for screening and their samples are sent to a laboratory, while the communication between the laboratory and CIS-FP is carried out by HL7 messages. The system calculates the Bethesda scores based on the KOPAC classifications and, depending on the results, schedule a sequel appointment.  RADventure is very pleased to contribute to the Cervical Cancer screening program. Currently there are over 70.000 clients registered in the system. More information: Fundashon Prevenshon


Canary Islands

For several years RADventure provides the Management Information System (called BCS) for the breast cancer screening implementation on the Canary Islands. We are very pleased to announce that the Canary Islands Government awarded the continuation of the support for this system. We look forward to continue our support for the breast cancer screening in the Canary Islands.



RADventure attended the 2016 ECR conference at Vienna. We appreciate the quality of sessions we were able to join. Several speakers talked about the future of cancer screening, and they all had one topic in common: Personalized Screening. It was nice to see that our screening software solutions already anticipate and support these new developments. We had the opportunity to show our screening solutions to interested organizations / delegations. ECR 2016: a great way to learn and share information about radiology solutions in healthcare. RADventure was glad to be a part of this!


RADventure supports the ROBINSCA project

Cardiovascular diseases are the primary cause of morbidity and mortality in Europe. Early detection (screening) and treatment for cardiovascular diseases in large groups of people without symptoms (general population) might have the opportunity to reduce cardiovascular-related morbidity and mortality. However, evidence is lacking whether the benefits of screening (e.g. reduced morbidity and mortality) justify the potential harms (e.g. unnecessary treatment, costs).

The ROBINSCA (Risk Or Benefit IN Screening for Cardiovascular disease) is the only large-scale population-based randomized controlled trial that investigates the cost-effectiveness of screening for cardiovascular diseases. About 39,000 participants will be randomized to either the control arm (no screening), intervention arm A (risk calculation by means of well-known risk factors) or intervention group B (risk calculation by means of coronary artery calcium scoring (CT scan)). After five years, these groups will be compared regarding differences in cardiovascular-related morbidity and mortality.

Based on over 15 years of experience with preventative cancer screening projects, RADventure has built the software to manage the logistic flow of this research program. The ROBINSCA-system connects to the population registry in The Netherlands to obtain and synchronize data. It manages the status of almost 400,000 initial individuals through invitations and risk assessments, study enrollment, randomization, planning, invitation management and the data collection from laboratories and scan centers. It provides extensive functionality to conduct complex sample investigations related to individual milestones and provides multiple modalities to communicate with participants. The system provides intuitive two-way interfaces for anonymized statistical processing.

Beginning of March 2015, the first 5,196 participants were randomized and enrolled in the study.

The RADventure Group is specializing in supporting and managing preventative screening programs and established several ICT systems for both national and international screening programs since the year 2000.


RADventure attended WEO Colorectal Cancer Screening Committee in Vienna

On the 17th of October RADventure attended the meeting of the Colorectal Cancer Screening Committee in Vienna. This committee is part of the World Endoscopy Organization (WEO).  The sessions provided valuable information on screening methodologies, tests and equipment, substantiated with the outcomes of multiple scientific research programs. RADventure co-sponsored the event because of it’s added value to our product development. For more information, please visit:

Contact Info

Computerweg 3

3542 DP Utrecht

The Netherlands

(+31) (0)88 77 647 47

Daily: 8.30AM to 5.30PM CET

Copyright RADventure 2024 © All Rights Reserved